FDA approves new cancer drug Copiktra (duvelisib) for use in CLL and SLL adult patients

lymphoma is the most common type of blood cancerThe three types of blood cancer treated by Copiktra are inert non-Hodgkin lymphoma (indolent non-Hodgkin lymphoma)yesterday (September 25), the U.SFDA(announced) that Verastem Oncology(duvelisib) to treat adult patients with recurrent/incurable chronic lymphatic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least two pre-treatment treatmentsat the same time the FDA approved Copiktra to treat adult patients with recurrent/incurable follicles (FL) who had received at least two pre-treatment treatmentsCopiktra, developed by VerastemVerastem, is an innovative oral inhibitor of PI3K protein kinaseIt can inhibit the activity of both PI3K-niand and PI3K-nichThese two protein kinases help support the survival and growth of cancerous B cellsCopiktra's new drug application was eligible for fda-granted reviewPreviously, Copiktra was also eligible for fast-track and orphan medicine sedated by the FDArelated studiesapproval for treatment of CLL and SLL are based on a multicenter random open label of the 3st Phase 3 ClinicalTrial(which compares the efficacy of duvelisib with the current standard therapy for treating CLL and SLL patients with recurrent/incurable CLL or SLL)Of the 196 patients who had received at least two treatments, the non-progressive survival period was 16.4 months in the duvelisib group and 9.1 months in the active control groupTotal mitigation rates (ORR) were 78% (duvelisib group) and 39% (active control group), respectivelytreatment FL approval is based on a single-arm multi-center Phase 2 clinical trialEighty-three FL patients who developed resistance to ritusximab and chemotherapy or radiotherapy were treated with duvelisibThe ORR was 42%, with 41% of the patients in partial remission and 1 patient in total remissionamong patients who received remission, 43% had remission periods of more than 6 months, and 17% had remission periods of more than 12 months